Blood serum miRNA: Non-invasive biomarkers for Alzheimer's disease

Geekiyanage, Hirosha; Jicha, Gregory A.; Nelson, Peter T.; Chan, Christina

doi:10.1016/j.expneurol.2011.11.026

Cited by 264 publications

(195 citation statements)

References 55 publications

Supporting

Mentioning

184

Contrasting

Unclassified

Order By: Relevance

“…Dong et al (2015) found that the expression of miR-93-5p in AD patients was 0.48 times that in control subjects, a finding consistent with those of the current study. Some studies have also reported the lower levels of miR-137, 181c, 9, 29a, and 29b in the serum of patients with mild cognitive impairment (Geekiyanage et al 2012). Although the expression levels of some of these miRNAs changed in the current study, the copy numbers were below 400; therefore, those miRNAs cannot be used as biomarkers.…”

Section: Discussioncontrasting

confidence: 61%

Lower Serum Levels of miR-29c-3p and miR-19b-3p as Biomarkers for Alzheimer’s Disease

et al. 2017

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are short noncoding RNA that participate in posttranscriptional gene regulation. However, little is understood about the roles of miRNAs in Alzheimer's disease (AD). In this study, we used next-generation sequencing on RNA extracted from the serum samples of 20 AD patients and 20 controls, yielding a total of 72 miRNAs with significantly changed expression levels. Among these candidates, we selected 9 miRNAs with most significant alteration in disease, and validated their expression levels using RT-qPCR analysis on serum samples from 45 AD patients and 40 control subjects. Thus, the serum levels of miR-146a-5p, 106b-3p, 195-5p, 20b-5p, and 497-5p were significantly higher, while those of miR-125b-3p, 29c-3p, 93-5p and 19b-3p were significantly lower in AD patients, compared with control subjects. Two miRNAs, miR-29c-3p and miR-19b-3p, were selected because both RNA deep-sequencing and q-PCR methods indicated lower serum levels of these miRNAs in AD patients. Computational analysis predicted that 3′-untranslated region of signal transduction and activator of transcription 3 (STAT3) mRNA is targeted both by miR-29c-3p and miR-19b-3p. Using SH-SY5Y human neuroblastoma cells, we showed that transfection with miR-29c-3p or miR-19b-3p inhibitor significantly increased STAT3 phosphorylation. Furthermore, Water maze test, which assesses the learning and memory deficits in rodents, showed that escape latency was significantly shorter in AD rats with overexpression of miR-29c-3p or miR-19b-3p than in control AD rats. These results suggest that miR-29c-3p or miR-19b-3p may contribute to the cognitive function. In conclusion, the serum levels of miR-29c-3p and miR-19b-3p are helpful biomarkers for AD.

show abstract

Section: Discussioncontrasting

confidence: 61%

Lower Serum Levels of miR-29c-3p and miR-19b-3p as Biomarkers for Alzheimer’s Disease

et al. 2017

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…The levels of these miRNAs were also reduced in the serum of AD risk factor models. Although the ability of these miRNAs to conclusively diagnose AD is currently unknown, it was suggested as a potential use for circulating miRNAs, along with other markers, as non-invasive and relatively inexpensive biomarkers for the early diagnosis of AD (62). However, circulating mRNAs could be useful in a complex neuropsychiatric disorder that involves disturbances in neural circuitry and synaptic function as in schizophrenia.…”

Section: Circulating Mirnas In Autoimmune Diseases Inflammatory and mentioning

confidence: 99%

Circulating microRNAs: New biomarkers in diagnosis, prognosis and treatment of cancer (Review)

Allegra

Alonci

Campo

et al. 2012

International Journal of Oncology

321

208

View full text Add to dashboard Cite

show abstract

“…The role for miR-137 in SZ pathogenesis was further corroborated by the validation of SZ-associated genes CSMD1, C10orf26, CACNA1C, and TCF4 as miR-137 targets [67]. Nevertheless, it is perhaps not surprising that miR-137 has not emerged as a (specific) SZ biomarker: similar to miR-134 and miR-15-107 family, miR-137 was found to be dysregulated in other diseases [68,69].…”

Section: Discussionmentioning

confidence: 91%

Deregulated microRNA expression in biospecimens from patients diagnosed with schizophrenia and bipolar disorder as a disease biomarker

Delalle

Kao

Choi

2014

Translational Neuroscience

View full text Add to dashboard Cite

The biological markers for schizophrenia (SZ) and bipolar disorder (BD) would represent a precious tool in evaluating the risk for the development of these common neuropsychiatric diseases and, possibly, in the prevention of either disease episodes and/or treatment efficiency monitoring. Since both SZ and BD are diseases with a significant genetic component, the research over the last decades has focused on the genes with altered function in the central nervous system (CNS) of individuals suffering from these illnesses. Recently, however, small non-coding RNA molecules (microRNAs, miRNAs, miRs) were shown to regulate the expression of human CNS genes involved in cell processes and functions negatively affected in neuropsychiatric disorders, including synaptic development and maturation, learning and memory. Differentially expressed sets of miRNAs have been reported in the tissues of SZ and BD patients in comparison to controls suggesting the emergence of a novel class of potential biomarkers. Here we review the reports on the changes in miRNA expression in postmortem brain tissue and peripheral blood in SZ and BD. We also evaluate the potential of miRNA packaged in exosomes, signaling vesicles released by neurons and glia, to contribute to the disaggregation of the molecular machinery underlying mental disorders and provide clinically useful biomarkers.

show abstract

Blood serum miRNA: Non-invasive biomarkers for Alzheimer's disease

Cited by 264 publications

References 55 publications

Lower Serum Levels of miR-29c-3p and miR-19b-3p as Biomarkers for Alzheimer’s Disease

Lower Serum Levels of miR-29c-3p and miR-19b-3p as Biomarkers for Alzheimer’s Disease

Circulating microRNAs: New biomarkers in diagnosis, prognosis and treatment of cancer (Review)

Deregulated microRNA expression in biospecimens from patients diagnosed with schizophrenia and bipolar disorder as a disease biomarker

Contact Info

Product

Resources

About